Posters

      Exploring Discriminant Capacity of Urinary CEMA as Combustion Marker in Tobacco Users - A Population Pharmacokinetic Approach

      Claussen, A.; Donelli, A.; Copalu, W.; Lama, N.; Weitkunat, R.; Haziza, C.; Lüdicke, F.

      Conference date
      Feb 22, 2019
      Conference name

      Society for Research on Nicotine and Tobacco (SRNT) 2019
      Link to more information
      Topic
      Summary

      Background: Population pharmacokinetics (PK) analysis was performed to characterize the concentration-time profile of urinary 2-cyanoethylmercapturic acid (CEMA), a marker of exposure to acrylonitrile, which is present in tobacco smoke but not in aerosol from uncombusted tobacco, such as the IQOS® heat-not-burn tobacco product. Methods: Data from four studies, assessing exposure reduction to harmful and potentially harmful constituents (HPHC) following IQOS use compared with HPHC exposure from smoking, were pooled for analysis. Modeling and simulations were conducted using the nonlinear mixed-effect method. Goodness-of-fit diagnostics and posterior predictive checks were used to evaluate the adequacy of the model fit and prediction. The potential of CEMA as a diagnostic marker to distinguish between smoking and non-combustible tobacco use was explored by means of receiver operating characteristics (ROC) analysis. Results: A total of 632 subjects, 322 training and 310 validation datasets, were available for analysis. CEMA was best described by a two-compartment linear dispersion with first-order absorption for product use. In the final PK model the elimination rate increased with increasing baseline CEMA and in subjects outside the U.S. region; the inter-compartmental rate constant was lower in smoking. Following single use, the levels of absorption of CEMA from IQOS were 1.3% of those absorbed from smoking. Model simulations were conducted assuming an average consumption of 13 sticks or cigarettes. The area under the ROC curve was 94% and 97% using simulated and observed CEMA values, respectively. A threshold of 40 [ng/mg creat.] resulted in a discriminant accuracy of 90% (false positive rate 2%; false negative rate 26%). Conclusions: The population PK model characterized the kinetics of CEMA adequately. Exploratory analysis showed an excellent performance for CEMA to discriminate between smoking and IQOS use.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.